1	Is Second dose of vaccination useful in previously SARS-CoV-2 infected Health Care
2	Workers?
3	Gauthier PEAN DE PONFILLY ^{1,2} , Benoît PILMIS ^{2,4} , Iheb EL KAIBI ³ , Nathalie CASTREAU ⁵ ,
4	Sophie LAPLANCHE ³ , and Alban LE MONNIER ^{1,2*}
5	1. Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
6 7	2. Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France
8	3. Laboratoire de Biologie Médicale, Groupe Hospitalier Saint-Joseph, Paris, France
9 10	4. Équipe Mobile de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France
11 12	5. Service de santé au travail, Groupe Hospitalier Paris Saint-Joseph, Paris, France
13	
14	Summary
15	
16	Vaccines are the most important public health measure to protect people from COVID-19
17	worldwide. In addition, healthcare workers account for a large number of infected people.
18	Then, protecting this population from COVID-19 seems crucial in the preservation of
19	healthcare systems. In a context of few doses available, serological assays could be useful to
20	decide whether one or two doses are needed. Our results show that a first dose of BNT162b2
21	mRNA vaccine seems to act as a boost after SARS-CoV-2 infection in healthcare workers with
22	a previous SARS-CoV-2 infection and a second dose might not be required.
23	
24	
25	
26 27 28 29 30 31 32	 * Corresponding author: Prof. Alban Le Monnier Service de Microbiologie clinique Groupe Hospitalier Paris Saint-Joseph 185 rue Raymond Losserand, 75014, Paris, France Tel: +33 1 44 12 79 32 Fax: + 33 1 44 12 35 13 Mail: alemonnier@ghpsj.fr NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 Introduction

34 Since the early 2020, a large pandemic due to the new and emergent coronavirus (SARS-CoV-2) spreads all over the world. While some countries have been able to contain the pandemic 35 with a combination of public health measures (extensive testing followed by isolation and 36 37 tracing of contacts, near-universal masking, and target quarantines), most countries have failed to stop the pandemic. Much hope now resides in the potential of SARS-CoV-2 vaccines 38 to reduce the risk of disease and infection. Strategies aimed to maximize the early impact of 39 vaccination in a context of few doses available [1]. As soon as early January 2021, large 40 41 vaccination campaign started in France first for populations at risk of severe COVID-19 but rapidly also for Healthcare workers (HCWs) more than 50 years or with underlying diseased, 42 then for all voluntary HCWs. Indeed, numerous studies have underlined the risk of nosocomial 43 transmission to and from healthcare workers in hospital settings [2,3]. 44

Then, the issue of vaccination of patients and HCWs with a history of recent or late SARS-CoV-2 related infection has become a major issue to reduce this risk. Currently, French guidelines recommends vaccination in those cohort that are recovered from COVID-19 since six months and to offer them only one dose [4]. Moreover, serological assays are not included in the decision-making strategy of vaccination.

50 We aimed to provide data on immune response induced by SARS-CoV-2 vaccines in real world 51 context that can support this choice. Here, we reported kinetics of production of antibodies 52 directed to the Spike protein of SARS CoV-2 after first, then second vaccine dose (conventional 53 prime-boost strategy recommended) in Health Care Workers.

54

55 Material and methods

All HCWs currently working at the Groupe Hospitalier Paris Saint-Joseph (Paris, France) and eligible to vaccination were proposed to be included in an observational cohort study after first then second dose of the BNT162b2 mRNA COVID-19 vaccine (Pfizer / BioNTech, Mainz, Germany).

They were divided in two groups: HCWs with a previous history of SARS-Cov-2 infection (COVID-19 (+)) and HCWs with no history of SARS-Cov-2 infection (COVID-19 (-)) according to

the result of RT-PCR and/or serology to confirm previous contact with SARS-CoV-2. Minimal
information were collected like sex, age, dates of first and second vaccine doses.

64 After agreement, HCWs have first serology 28 days after the first dose before receiving the 65 second dose, then a second serology 21 to 28 days after.

66 HCWs with a history of COVID-19 came from the ongoing PERSOCOVID longitudinal 67 observational cohort study. Briefly, these colleagues have benefited of a longitudinal 68 serological follow-up since the onset of the disease. For each of them, the level of antibodies 69 directed to Spike protein before vaccination was known. No COVID-19 recently diagnosed in 70 the last three months were included in the study, according to French health agencies 71 recommendations.

Serological assays used the quantitative test (SARS-CoV-2 IgG II Quant, Architect System, Abbott) for detecting serum antibodies directed to receptor-binding domain (RBD) of the Spike-1 protein of SARS-CoV-2. Quantitative results are converted in AU/mL. Dilution was performed for each result beyond 40,000 AU/mL according to the manufacturer's instructions. The positivity threshold was 50 AU/mL according to manufacturer's instructions.

For the statistical comparison, a Shapiro-Wilk test for normality of distribution was first
performed and a t-student test was performed for continuous variables, using the R software
version 3.1.3[4]. Significance was considered if p<0.05.

80

81 Results

82 Seventy-three HCWs gave consent to participated to this study and distributed in 29 (39.7%) COVID-19 (+) and 44 (60.3%) COVID-19 (-). No case of severe COVID-19 was recruited in this 83 study and median [IQR] age of the included HCWs was 43.5 [34 – 56.5] years old. The median 84 time from first dose to serology was 25 days and 28 days from second dose to second serology. 85 We first reported a significant difference in anti-Spike antibody levels (median [IQR]) around 86 46-fold higher in COVID-19 (+) (28111 [15032-33967] AU/mL) than in COVID-19 (-) (642 [338-87 1170] AU/mL) (p < 0.001) after the first dose. Antibody levels produced after the first dose in 88 89 COVID-19 (-) are quite similar than those observed in COVID-19 (+) (324 [116-630] AU/mL) not 90 yet vaccinated. In the latter, the antibody levels increased on a mean by 88-fold after the first 91 vaccine dose.

After the first vaccine dose, COVID-19 (-) presented a median level of IgG anti-Spike at 617 [338-1147] AU/mL and their median level increases significantly 28 days after their second dose at 9711 [4978-15473] AU/mL (p < 0.001). Previous infection seemed to be analogous to natural immune priming.

96 After the second dose, COVID-19 (-) significantly increased their antibody levels (10491

97 [5341-16193] AU/mL) without, however, reaching the levels generally observed for COVID-

98 19 (+) after a single dose. For COVID-19 (+), we observed that the second dose did not

significantly increase their antibody level (35459 [11565-38500] AU/mL; *p*=0.18).

100

101 Discussion

Following a single dose of BNT162b2, HCWs with a previous SARS-CoV-2 infection have significantly higher antibody response than naive HCWs. The first dose of the vaccine seems to act as a boost after SARS-CoV-2 infection and a second dose might not be required in case of previous SARS-CoV-2 infections.

A delayed booster beyond the 30 days initially recommended for the BNT162b2/Pfizer vaccine
 could then be proposed. This is an important element in the current context of few doses
 available to accelerate vaccine rollout [1].

Furthermore, COVID-19 is associated with an increase in HCWs absenteeism making themanagement of a public health crisis even more complicated [5].

111 However, we also reported a paradoxically lower response than those expected for one 112 COVID-19 (+). This HCW presented a positive RT-PCR and a positive serological assay 113 confirming previous contact with SARS-CoV-2. This suggests that the use of serological tests could be useful to confirm adequate vaccine response without, however, the correlate of 114 115 protection value. Indeed, here no neutralization assays have been carried out because they are difficult to set up on a routine basis [6]. For HCWs with a previous SARS-CoV-2 infection, a 116 determination of the antibodies level produced after the first dose can be proposed just 117 before the second dose to decide whether or not it is necessary. 118

Kinetics of natural anti-Spike antibody levels decrease more or less rapidly according to initial
level of IgG produced. In some cases, anti-Spike antibodies become undetectable beyond six

- 121 or eight months for some HCWS or some patients [7,8]. This also raises the question of the
- 122 durability of the antibodies produced either after prime or boosted vaccination as for COVID-
- 123 19 course and the impact of high initial antibodies levels.
- 124 Our study provides additional information on the positioning and usefulness of serology in the
- 125 COVID-19 vaccine strategy in order to maximize coverage and impact.
- 126

127 Acknowledgement:

- 128 We thank all colleagues who accept to participate to this study, in particular staff of the
- 129 Occupational Medicine Department: Morgane PAUILLAT, Mathilde HERR, Dr Priscilla SAVIN,
- 130 and Dr Patricia MALARDY.
- 131

132 References

- [1] Henn W. Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and
 necessary measures for global immunity. Vaccine 2020;38:5396–7.
- 135 https://doi.org/10.1016/j.vaccine.2020.06.058.
- [2] Abbas M, Robalo Nunes T, Martischang R, Zingg W, Iten A, Pittet D, et al. Nosocomial
 transmission and outbreaks of coronavirus disease 2019: the need to protect both
 patients and healthcare workers. Antimicrob Resist Infect Control 2021;10:7.
 https://doi.org/10.1186/s13756-020-00875-7.
- [3] Schwierzeck V, König JC, Kühn J, Mellmann A, Correa-Martínez CL, Omran H, et al. First
 Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in
 a Pediatric Dialysis Unit. Clin Infect Dis Off Publ Infect Dis Soc Am 2021;72:265–70.
 https://doi.org/10.1093/cid/ciaa491.
- [4] HAS. Stratégie de vaccination contre le SARS-CoV-2 : Vaccination des personnes ayant un antécédent de Covid-19. 11/02/2021 n.d.
- [5] Groenewold MR, Burrer SL, Ahmed F, Uzicanin A, Free H, Luckhaupt SE. Increases in
 Health-Related Workplace Absenteeism Among Workers in Essential Critical
- Infrastructure Occupations During the COVID-19 Pandemic United States, March–April
 2020. Morb Mortal Wkly Rep 2020;69:853–8.
- 150 https://doi.org/10.15585/mmwr.mm6927a1.
- [6] Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. COVID-19 neutralizing antibodies predict disease severity and survival. Cell 2021;184:476-488.e11.
 https://doi.org/10.1016/j.cell.2020.12.015.
- 154 [7] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to 155 SARS-CoV-2 assessed for up to 8 months after infection. Science 2021.
- 156 https://doi.org/10.1126/science.abf4063.

- 157 [8] Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of
- 158 neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat
- 159 Commun 2021;12. https://doi.org/10.1038/s41467-021-21111-9.
- 160
- 161
- 162




Figure 1. Evolution of anti-Spike IgG titer expressed in log10 AU/mL during the vaccinationprotocol, according to history of COVID-19.